PRO 2000 (PRO-2000)

05/19/1997 - " In laboratory studies, PRO 2000 blocked infection by a wide variety of HIV strains and also was active against herpes simplex virus." Clinical studies currently are underway to assess the safety of PRO 2000 Gel in healthy female volunteers. "
10/16/2010 - "We randomly assigned sexually active women, aged 18 years or older (≥16 years in Tanzania and Uganda) without HIV-1 infection in a 1:1:1 ratio to 2% PRO2000, 0·5% PRO2000, or placebo gel groups for 52 weeks (up to 104 weeks in Uganda). "
08/01/2006 - "Our results demonstrate that PRO 2000 is a potent inhibitor of R5 HIV-1 infection and dissemination pathways in human cervical explants. "
08/01/2006 - "PRO 2000, but not DxS, also inhibited HIV-1 binding to DC-SIGN+ cells and trans infection of co-cultured target cells. "
08/01/2006 - "PRO 2000 efficiently inhibited infection of cervical explants and dissemination of virus by migratory DC. "

08/01/2014 - "Incidences of STIs were determined by study arm, and HRs of BufferGel and PRO 2000 versus placebo gel or no gel control groups were computed using discrete time Andersen-Gill proportional hazards model. "
08/01/2014 - "Between 2005 and 2007, 3099 women were enrolled in HIV Prevention Trials Network (HPTN) protocol 035, a phase II/IIb evaluation of the safety and effectiveness of BufferGel and PRO 2000 for prevention of STIs, including Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV). "
07/01/2009 - "These include the Mwanza study of syndromic management of sexually transmitted diseases and three male circumcision trials in East Africa; a microbicide trial reported in 2009 shows substantial promise for the efficacy of PRO 2000 (0.5% gel). "
08/01/2014 - "HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women."
08/01/2014 - "To estimate the effectiveness of candidate microbicides BufferGel and 0.5% PRO 2000 Gel (P) (PRO 2000) for prevention of non-ulcerative sexually transmitted infections (STIs). "

02/01/2004 - "We assessed the efficacy of 7 promising formulated agents--CarraGuard, Ushercell, [poly]sodium 4-styrene sulfonate (T-PSS), PRO 2000, ACIDFORM, cellulose acetate phthalate (CAP), and BufferGel--by use of a mouse model of Neisseria gonorrhoeae genital tract infection. "

09/01/1998 - "The 12th World AIDS Conference exhibited presentations on the safety and efficacy of microbicide products currently in development, including: Pro-2000 (Procept), BufferGel ( ReProtect), Protectaid (Biopharm Laboratories), and C31G (Biosyn). "

05/01/2008 - "Continuous exposure to PRO 2000 during MDDC-target cell coculture effectively inhibited HIV infection of target cells. "
02/01/2008 - "Indevus Pharmaceuticals Inc, under license from Paligent Inc, is developing PRO-2000, an antimicrobial gel for the prevention of HIV infection. "
02/01/2008 - "PRO-2000, an antimicrobial gel for the potential prevention of HIV infection."
05/01/2008 - "The sulfonated polyanion PRO 2000, a candidate topical microbicide now in phase II/III clinical trials, blocks HIV infection of cervical tissue in vitro. "
08/01/2012 - "Topical products that were ineffective in preventing HIV infection include BufferGel, Carraguard, and PRO 2000. "